mRNA future

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R) May 31, 2024 Moderna, today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna. Stéphane Bancel, Chief Executive Officer of Moderna. The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season. Moderna has filed for mRNA-1345 approval with regulators in multiple markets a